XL765: Clinical Trials

4 trials of XL765, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 4
Phase 12Completed 2

Follow XL765: new trials by email Literature Review of XL765 trials Research Report on XL765

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
Pimasertib once daily, Pimasertib placebo, SAR245409 placebo - Ovarian Cancer
Phase 2CompletedEMD Serono652013-09-302018-12-12
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
SAR245408, SAR245409 - Neoplasm Malignant
Phase 1 / Phase 2CompletedSanofi612012-07-202022-04-19
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
SAR245409 - Lymphoma
Phase 2CompletedSanofi1672011-10-012016-03-17
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
XL147 (SAR245408), XL765 (SAR245409), letrozole (Femara) - Breast Cancer
Phase 1 / Phase 2CompletedSanofi722010-06-012016-06-03

Conditions studied

Breast Neoplasms (1)  ·  Lymphoma (1)  ·  Neoplasms (1)  ·  Ovarian Neoplasms (1)

Sponsors

Sanofi (3)  ·  EMD Serono (1)

Countries

France (4)  ·  United States (4)  ·  Belgium (3)  ·  Spain (3)  ·  Australia (2)  ·  Canada (1)  ·  Germany (1)  ·  Netherlands (1)  ·  Poland (1)

Results publications

PMID 29550382